1. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer. 2018;103:356-38. Available from: URL doi: 10.1016/j.ejca.2018.07.005.

2. Ulldemolins A, Seras-Franzoso J, Andrade F, Rafael D, Abasolo I, Gener P, et al. Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics. Cancer Drug Resist. 2021;4(1):44-68. Available from: URL doi: 10.20517/cdr.2020.59.

3. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 2008;8(1):59-73. Available from: URL doi: 10.1038/nri2216.

4. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, et al. Nanoparticle-Based Drug Delivery in Cancer Therapy and its Role in Overcoming Drug Resistance. Front. Mol. Biosci. 2020;7: 193. Available from: URL doi: 10.3389/fmolb.2020.00193.

5. Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141-160. Available from: URL doi: 10.20517/cdr.2019.10.

6. Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018;3(1):7. Available from: URL doi: 10.1038/s41392-017-0004-3.

7. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release. 2000;65(1):271-284. Available from: URL doi: 10.1016/s0168-3659(99)00248-5.

8. Koo H, Huh MS, Sun I-C, Yuk SH, Choi K, Kim K, et al. In Vivo Targeted Delivery of Nanoparticles for Theranosis. Acc. Chem. Res. 2011;44(10):1018-1028. Available from: URL doi: 10.1021/ar2000138.

9. Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017;7(3):339-348. Available from: URL doi: 10.15171/apb.2017.041.

10. Fülöp T, Kozma GT, Vashegyi I, Mészáros T, Rosivall L, Urbanics R, et al. Liposome-induced hypersensitivity reactions: Risk reduction by design of safe infusion protocols in pigs. J. Control Release. 2019;309:333-338. Available from: URL doi: 10.1016/j.jconrel.2019.07.005.

11. Xu H, He C, Liu Y, Jiang J, Ma T. Novel therapeutic modalities and drug delivery - erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations. Artif Cells Nanomed Biotechnol. 2018;46(8):1902-1907. Available from: URL doi: 10.1080/21691401.2017.1396222.

12. Bakhtiary Z, Barar J, Aghanejad A, Saei AA, Nemati E, Ezzati Nazhad Dolatabadi J, et al. Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer. Drug Dev. Ind. Pharm.2017;43(8):1244-1253. Available from: URL doi: 10.1080/03639045.2017.1310223.

13. Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: A novel drug targeting carrier. J. Drug Deliv. Sci.Technol. 2019;51: 255-267. Available from: URL doi: 10.1016/j.jddst.2019.02.017.

14. Balguri SP. Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues. Eur J Pharm Biopharm. 2016;109:224-235. Available from: URL doi: 10.1016/j.ejpb.2016.10.015.

15. Barghi L, Aghanejad A, Valizadeh H, Barar J, Asgari D. Modified synthesis of erlotinib hydrochloride. Adv Pharm Bull. 2012;2(1):119-122. Available from: URL doi: 10.5681/apb.2012.017.

16. Barghi L, Asgari D, Barar J, Nakhlband A, Valizadeh H. Synthesis, characterization and in vitro anti-tumoral evaluation of Erlotinib-PCEC nanoparticles. APJCP. 2015;15(23):10281-10287. Available from: URL doi: 10.7314/apjcp.2014.15.23.10281.

17. Marslin G, Sheeba CJ, Kalaichelvan VK, Manavalan R, Neelakanta Reddy P, Franklin G. Poly (D, L-lactic-co-glycolic acid) Nanoencapsulation Reduces Erlotinib-Induced Subacute Toxicity in Rat. J Biomed Nanotechnol. 2009;5(5):464-471. Available from: URL doi: 10.1166/jbn.2009.1075.

18. Werner ME, Cummings ND, Sethi M, Wang EC, Sukumar R, Moore DT, et al. Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2013;86(3):463-468. Available from: URL doi: 10.1016/j.ijrobp.2013.02.009.

19. Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138-157. Available from: URL doi: 10.1016/j.jconrel.2014.12.030.

20. Yu X, Di Y, Xie C, Song Y, He H, Li H, et al. An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line. Int J Nanomedicine. 2015;10:6825-6834. Available from: URL doi: 10.2147/IJN.S93835.

21. Moradpour Z, Barghi L. Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors. J Pharm Pharm Sci. 2019;22(1):37-48. Available from: URL doi: 10.18433/jpps29891.

22. Wei Y, Xu S, Wang F, Zou A, Zhang S, Xiong Y, et al. A novel combined micellar system of lapatinib and paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor-2 positive breast tumor in vitro. J. Pharm. Sci. 2015;104(1):165-177. Available from: URL doi: 10.1002/jps.24234.

23. Hu H, Lin Z, He B, Dai W, Wang X, Wang J, et al. A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel. J Control Release. 2015;220(Pt A):189-200. Available from: URL doi: 10.1016/j.jconrel.2015.10.018.

24. Setareh J, Jaleh V. Co-delivery of Curcumin and Imatinib by Nanostructured Lipid Carriers in the Treatment of Lymphoma. Int Pharm Acta. 2018;1(1):37-38. Available from: URL doi: 10.22037/ipa.v1i1.19945.

25. Katiyar SS, Muntimadugu E, Rafeeqi TA, Domb AJ, Khan W. Co-delivery of rapamycin- and piperine-loaded polymeric nanoparticles for breast cancer treatment. Drug Deliv. 2016;23(7):2608-2616. Available from: URL doi: 10.3109/10717544.2015.1039667.

26. Khaledi S, Jafari S, Hamidi S, Molavi O, Davaran S. Preparation and characterization of PLGA-PEG-PLGA polymeric nanoparticles for co-delivery of 5-Fluorouracil and Chrysin. J. Biomater. Sci. Polym. Ed. 2020;31(9):1107-1126. Available from: URL doi: 10.1080/09205063.2020.1743946.

27. Ventola CL. Progress in Nanomedicine: Approved and Investigational Nanodrugs. P&T. 2017;42(12):742-755.

28. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54(4):987-992.

29. Hamad I, Moghimi SM. Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug. Expert Opin. Drug Deliv. 2008;5(2):205-219. Available from: URL doi: 10.1517/17425247.5.2.205.

30. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 2009;4:99. Available from: URL doi: 10.2147/ijn.s3061.

31. Mayer LD, Tardi P, Louie AC. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. Int J Nanomedicine. 2019;14: 3819- 3830. Available from: URL doi: 10.2147/IJN.S139450.